Latest News for CYBN
I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003. HELP is positioned to benefit from expedited FDA pathways and increased institutional support, particularly for major depressive disorder and PTSD indications. The market undervalues HELP, trading near cash value with a 0.84x forward price-to-book and an $85M EV versus $195M in cash.
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CYBN.
Senate Trading
No Senate trades found for CYBN.
U.S. House Trading
No House trades found for CYBN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.